Novo Nordisk anti-inflammation drug misses in heart disease study

Elaine’s tales discover the growth in new weight problems therapies, new drug fee fashions, the methods firms are affected by FDA adjustments, and the rising psychedelics drug sector. She co-writes The Readout e-newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You may attain Elaine on Sign at elaineywchen.70.

Novo Nordisk stated Friday that its investigational anti-inflammatory drug didn’t scale back the danger of main coronary heart occasions in a pivotal trial, elevating questions concerning the more and more fashionable strategy of concentrating on irritation to forestall cardiovascular problems.

In a Section 3 research that enrolled over 6,300 individuals with coronary heart illness, kidney illness, and irritation, the drug, ziltivekimab, did decrease markers of irritation, Novo stated. Nevertheless, that didn’t translate into a discount in threat of main problems, together with cardiovascular-related demise, coronary heart assault, or stroke.

Novo shares had been down about 7% Friday.